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Immune DNA signature of T-cell 
infiltration in breast tumor exomes
Eric Levy1,2, Rachel Marty2,3, Valentina Gárate Calderón4,5, Brian Woo6, Michelle Dow1,2, 
Ricardo Armisen4,5, Hannah Carter3,6,7 & Olivier Harismendy1,6
Tumor infiltrating lymphocytes (TILs) have been associated with favorable prognosis in multiple tumor 
types. The Cancer Genome Atlas (TCGA) represents the largest collection of cancer molecular data, but 
lacks detailed information about the immune environment. Here, we show that exome reads mapping 
to the complementarity-determining-region 3 (CDR3) of mature T-cell receptor beta (TCRB) can be used 
as an immune DNA (iDNA) signature. Specifically, we propose a method to identify CDR3 reads in a 
breast tumor exome and validate it using deep TCRB sequencing. In 1,078 TCGA breast cancer exomes, 
the fraction of CDR3 reads was associated with TILs fraction, tumor purity, adaptive immunity gene 
expression signatures and improved survival in Her2+ patients. Only 2/839 TCRB clonotypes were 
shared between patients and none associated with a specific HLA allele or somatic driver mutations. The 
iDNA biomarker enriches the comprehensive dataset collected through TCGA, revealing associations 
with other molecular features and clinical outcomes.
In breast cancer, the presence of tumor infiltrating lymphocytes (TILs), and more specifically T-lymphocytes, is 
associated with good survival1,2 and response to neo-adjuvant treatment3,4. The different breast cancer subtypes 
do not significantly differ in fraction of TILs, which is relatively low5, but this metric has prognostic or predictive 
value in triple negative breast cancer (TNBC) and Her2+ breast cancer4,6,7. In order to further distinguish the 
different cell type populations, other studies have used immunohistochemistry to detect cell surface markers (e.g. 
CD3, CD8, CD20), demonstrating, for example, that the predictive value of B-cell infiltration is independent of 
cancer subtype or other clinical factors8, or that CD8+ T-cell infiltration is of good prognosis in basal TNBC5. 
A related clinical-grade assay, the immunoscore, is being proposed for colorectal cancer9, but requires further 
evaluation in breast cancer3.
Analysis of gene expression signatures can also be used to infer the presence of immune cells and their role in 
immune signaling within the tumor microenvironment. High levels of a TIL-associated signature is associated 
with good prognosis in ER- breast cancer10. Gene expression signatures specific to T-cells5,11 and B-cells12 also 
have prognostic or predictive value in specific cancer subtypes. Interestingly, while the expression of metagenes is 
not different between breast cancer subtypes, their prognostic significance varies. For example, the expression of 
a T-cell metagene is associated with good prognosis in ER- or Her2+ tumors11. More recently, the gene expression 
measurements in heterogeneous tumor samples have been deconvolved using machine learning to determine the 
relative abundance of up to 22 immune cell types13. This association revealed an opposite survival association of 
plasma cells and neutrophils14.
Correlations have been observed between the extent of T-cell infiltration and clinical prognosis in breast 
cancer subtypes. However, this effect is indirect, related to the T-cells’ role in tumor control and is dependent 
on their tumor reactivity. Thus a deeper characterization of the T-cell repertoire can provide more information 
about its diversity, the associated tumor reactivity, and antigen specificity. Recent technical progress has enabled 
the characterization of T-cell repertoires by deep sequencing of the VDJ rearrangement at the complementa-
rity determining region 3 (CDR3) of TCRB15, and has been used to observe at an unprecedented resolution the 
clonal diversity of T-cells during infection and in solid tumors15–17. Deep repertoire sequencing performed in 
tumors of the colon17, ovary18, kidney19, pancreas20, or lung21 have addressed methodological challenges and 
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have confirmed the diversity and specific landscape of TILs. However, the technical validity and clinical utility 
of TCR repertoire characterization in tumors remains to be established. In particular, it is not yet clear whether 
the quantity (fraction of T-cells) or the diversity (relative abundance of specific clones) is more important to 
predict disease progression and response to treatment. Similarly, we do not know the extent of clonotype sharing 
between patients or between tumor, lymph nodes, and metastasis of the same patient or whether any clinical 
association with these patterns can be determined. Overall, the understanding of the tumor immune environ-
ment remains fragmented, and a more comprehensive integrated approach is needed to characterize the tumor 
immune landscape, as recently suggested by the colorectal cancer anti-genome study22. Comprehensive profiling 
of the immune environment, including T-cell repertoire, needs to be expanded to larger, well-annotated cohorts 
to establish its potential utility. The Cancer Genome Atlas (TCGA) provides a large resource of molecular data 
that can be interrogated for this immune environment23. Here, we show that it is possible to re-analyze tumor 
exomes and transcriptomes from TCGA to quantify and characterize infiltrating T-cells through the detection 
of a rearranged CDR3 of the TCRB gene. We first establish the feasibility of the approach by characterizing the 
rearranged TCR repertoire using deep sequencing of a breast cancer specimen and comparing the resulting clo-
notypes to the ones identified in the whole exome sequence of the same sample. We then identify CDR3 reads in 
TCGA breast cancer tumors, and show their correlation with other markers of immune infiltration. We further 
evaluate their prognostic value in breast cancer subtype and investigate clonotype diversity and sharing between 
patients and specimens.
Results
Deep TCR repertoire sequencing. We sequenced the repertoire of three triple negative breast cancer 
(TNBC) samples selected for their variable TIL contents. Two samples had a high amount of infiltration (45% and 
40%), and one sample was chosen as a negative control (0%). Starting from 5 μ g of DNA (~8 × 105 total cells), we 
identified between 15 × 103 and 30 × 103 CDR3 rearrangements per tumor (Supplementary Fig. S1). Interestingly, 
even the tumor sample with no histological evidence of TILs shows multiple rearrangements, suggesting a limi-
tation of histological evaluation using a selected tissue section. The assay developed by Adaptive Biotechnologies 
includes a synthetic repertoire of 858 rearranged TCRB loci spiked into the PCR reaction, allowing for correction 
of PCR amplification bias by measuring this reference pool before and after amplification24. Thanks to these 
internal standards, the assay was able to precisely estimate the abundance of each clone and the overall clonality 
of each sample. The most clonal sample (OX1285: clonality = 0.22) contained the most abundant clone at 8% 
prevalence. In contrast, the two other samples had clonalities of 0.15 and 0.09, and the most abundant clone at 
1.7% each. The abundance of each clone was highly reproducible between two adjacent tissue sections (r = 0.99), 
suggesting a local homogeneity of the T-cell population (Fig. 1a). In complement to this data generation, we also 
evaluated the feasibility of using archival FFPE specimens for deep TCRB amplicon sequencing. Two samples 
showing the most fragmented DNA (average size <1.1 kb) had poor overall TCRB representation when com-
pared to the matched frozen. The least fragmented sample had the most reproducible results when compared to 
Figure 1. Identification of CRD3 reads in whole-exome data. (a) Clonotype abundance determined by deep 
repertoire sequencing (ImmunoSeq) in two adjacent breast cancer tissue sections. (b) Workflow to extract and 
identify rearranged CDR3 reads from exome datasets. (c) Comparison of the number of CDR3 reads identified 
by each clonotyping tools. The number in parenthesis indicates the subset of clonotypes also identified by deep 
repertoire sequencing. (d) Fraction of clipped reads mapped to the TCR region in the exome BAM file. The 
expected is estimated from all mapped reads in the exome.
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a matched frozen with an overall underestimate of the absolute clonotype frequency (Supplementary Fig. S1). 
This demonstrates that by using stringent DNA sample quality control, archival samples may be used for deep 
repertoire sequencing, albeit resulting in reduced accuracy.
Identification of CDR3 reads in tumor exomes. Sequencing a full, deep repertoire of TILs is costly 
and requires large amounts of DNA to ensure that sufficient clonal diversity is being captured. We thus sought 
to determine whether any of the TCRB clonotypes could be identified in exome sequencing data, which would 
permit the use of public cancer genomic data. Indeed, most exome capture kits contain probes overlapping the V 
and J genes of the TCRB locus. While such probes have been designed to capture the naïve TCR region, it is likely 
that a rearranged DNA fragment can be captured if it has sufficient overlap with the reference sequence to allow 
probe hybridization. To test this hypothesis, we sequenced 205 × 106 reads from the exome of sample OX1285, 
for which we obtained deep repertoire data (Supplementary Table S1). Of these, 784 × 103 reads did not map to 
the reference genome and 241 × 103 mapped to the reference TCRB locus. In order to identify reads mapping to 
a rearranged CDR3 domain of TCRB (referred to as CDR3 reads), we benchmarked three different tools: clono-
typR25, IM-SEQ26 and MiTCR27 (Fig. 1b), each originally designed to analyze deep repertoire sequencing exper-
iments. Each tool identified between 10 and 38 reads assigned to a CDR3 (Table 1). Across all three methods, we 
identified a total of 26 clonotypes, 15 of which were present in the deep repertoire dataset (Fig. 1c). Interestingly, 
60% of the CDR3 reads mapped imperfectly (clipped reads) to the reference TCRB locus (Fig. 1d), consistent 
with their mature TCRB origin and suboptimal alignment to the naïve TCRB genes. Fourteen clonotypes were 
identified by two or more methods. ClonotypR was the most stringent, only finding 6 clonotypes, all identified 
by the other tools. In contrast, MiTCR was the most lenient, with 7 unique clonotypes, 2 of which were present 
in the deep repertoire. Overall, IMSEQ offered the best compromise between sensitivity – 72% present in deep 
sequencing – and specificity – 94% shared with another tool – and was used for the rest of the analysis. The frac-
tion of CDR3 reads detected by IMSEQ is 0.09 reads per million reads (RPM) sequenced. Interestingly, assuming 
that this tumor had 20–40% of infiltrating T-cells, this value was consistent with the order of magnitude estimated 
by simulations (~10−1 – Supplementary Fig. S2 and Methods). The same simulation also suggested that, at typical 
exome sequencing coverage depth (100 fold), CDR3 reads could be detected in tumors with more than 3% T-cell 
infiltration. These results provide evidence that genuine CDR3 reads can be identified in exome sequencing data 
from a bulk tumor.
Number of reads supporting each 
clone in the exome data
Clone ID ClonotypeR IMSEQ MiTCR
ImmunoSeq 
Abundance (%)
c1 1 > 0* 6 8.10
c2 0 0 1 1.67
c3 0 1 1 0.89
c4 0 2 2 0.71
c5 0 1 1 0.52
c6 0 2 2 0.24
c7 0 1 1 0.21
c8 0 1 1 0.13
c9 0 1 0 0.12
c10 0 1 1 0.06
c11 0 > 0* 1 0.04
c12 1 1 1 0.03
c13 3 > 0* 3 0.02
c14 0 > 0* 1 0.01
c15 0 0 1 0.003
c16 2 2 0 NA
c17 0 1 1 NA
c18 0 0 1 NA
c19 0 0 1 NA
c20 0 0 1 NA
c21 0 0 1 NA
c22 1 1 1 NA
c23 0 > 0* 2 NA
c24 0 0 2 NA
c25 2 2 2 NA
c26 0 0 3 NA
Table 1.  Distribution of clonotypes identified in OX1285 exome using three CDR3 detection tools.  
(*)  Indicates rescued out-of-frame CDR3 reads in IMSEQ.
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Identification of CDR3 reads in the TCGA breast cancer exomes. Using the approach validated 
above, we analyzed the exome sequences of 1078 breast cancer tumors characterized through TCGA. We identi-
fied CDR3 reads in 473/1,078 (44%) tumors (Supplementary Table S2). For some of the downstream analysis, we 
smoothed the normalized CDR3 read content of each tumor into an immune DNA (iDNA) score: 0 for absence 
of CDR3 reads, and 1–10 for the increasing deciles of the distribution of normalized CDR3 read count (CDR3 
RPM). CDR3 RPM was associated with high TILs (p < 3 × 10−7 - Wilcoxon test). Indeed, only 19% of the tumors 
with no CDR3 reads (iDNA = 0) had more than 5% TILs, in contrast to 49% of the tumors with an iDNA score of 
10 (Fig. 2a). Importantly, TIL measurements refers to total TILs, not only T-cells, and this measurement may vary 
between sample collection sites and pathologists, despite efforts to standardize it3. For a more quantitative evalu-
ation, we chose to compare the fraction of tumor CDR3 reads to the tumor molecular purity. Specifically, we used 
the consensus purity estimate (CPE) measurement, which is the median of the results of four purity estimation 
methods, after normalization28. We observed that the fraction of CDR3 reads was inversely correlated (r = − 0.39) 
with tumor purity, with 43% of tumors without CDR3 reads having purity higher than 80%, in contrast to only 
4% of the tumors with an iDNA score of 10 (Fig. 2b). These results suggest that the CDR3 reads identified in the 
tumor exome truly originate from T-cells, and that their relative abundance is directly associated with the fraction 
of infiltrating lymphocytes.
iDNA score correlates with adaptive immunity expression signatures. In order to further explore 
the variation in iDNA scores, we used the level of gene expression to measure the relative enrichment for 22 
immune cell signatures13 in each tumor using GSVA29. We performed unsupervised hierarchical cluster-
ing according to GSVA scores. While expression signatures of different immune cells are often correlated, the 
top four branches of the clustering dendrogram represent 4 distinct groups of tumors: immune low (n = 458), 
mixed-adaptive (n = 159), mixed-innate (n = 149) and high (n = 307) (Fig. 2c). Seventy five percent of the 
tumors in the immune-low group did not have CDR3 reads (iDNA score = 0, Fig. 2d). In contrast, 65% of the 
immune-high tumors had CDR3 reads (iDNA score > 0). The immune-high group showed high levels of both 
adaptive and innate signatures. In contrast, the immune-mixed groups showed a clear distinction in activity levels 
of adaptive and innate immune cells. For tumor with iDNA scores greater than 0, the CDR3 RPM was higher in 
mixed-adaptive than mixed-innate groups, and the latter was not different from the immune-low group (Fig. 2e). 
These results indicate that the abundance of CDR3 reads in exomes is correlated with known expression signa-
tures of adaptive immunity.
CDR3 read content associates with survivalο. The fraction of tumors positive for iDNA was not differ-
ent between breast cancer subtypes (Fig. 3a). We show, however, that a positive iDNA score was associated with 
Figure 2. Association between iDNA score and the tumor immune-environment. (a) Fraction of tumors 
with more than 5% TILs in each iDNA score. (b) Fraction of tumors with more than 80% tumor purity in 
each iDNA score. (c) Clustering of 1072 breast tumors according to the GSVA score (red:high, blue:low) of 
22 immune gene signatures. The four main clusters, high (red), mixed adaptive (dark orange), mixed innate 
(light orange) and low (yellow) are labeled on the y-axis. (d) Distribution of tumors between the four immune 
signature groups with increasing iDNA scores. (e) Distribution of the CDR3 reads normalized abundance in 
tumors of the four immune signature groups (* ) p < 0.01, t-test. Only tumors with CDR3 reads are included.
www.nature.com/scientificreports/
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better overall survival (HR = 3.17 [1.18–8.51], p = 0.022) in Her2+ breast cancer (Fig. 3b), but not in hormone 
positive, Her2 negative (HR+ /Her2− ) or TNBC (Supplementary Fig. S3). Most Her2+ patients in the TCGA 
cohort were likely treated with anti-Her2 antibody therapy. Therefore, the iDNA score is predictive rather than 
prognostic for the Her2+ subtype. Interestingly, the fraction of TILs alone was not predictive of response in 
Her2+ tumors (Fig. 3c), suggesting the superiority of a DNA based measurement of mature T-cell content over 
the histological estimate of lymphocyte content.
TCRB expression and clonal diversity and sharing. We then asked whether the CDR3 sequences 
identified in the tumor exome were expressed and how they relate to the overall expression of the TCRB gene. 
Of the 1,074 tumor specimens with available transcriptome data, we were able to identify CDR3 reads in 906 
(84%) of them. The fraction of CDR3 reads in the RNA is correlated with the overall TCRB expression level 
(including non-CDR3 reads - r = 0.40 p < 10−16 – Fig. 4a). There were 435 tumors with evidence of CDR3 reads 
in both tumor DNA and RNA, and the fraction of CDR3 reads in the RNA and DNA was correlated (r = 0.33, 
p = 6.304 × 10−13, Fig. 4b). Interestingly, the overall expression of the TCRB gene increased from tumors with 
no CDR3 in RNA nor in DNA (N = 132), CDR3 reads in DNA only (N = 36), in RNA only (N = 471) or in both 
(N = 435 Fig. 4c p < 0.001 - ANOVA). This observation suggests that some tumors may have few infiltrating 
T-cells (exome CDR3 negative), but these T-cells express sufficient levels of TCRB for the CDR3 to be detected in 
the transcriptome. Conversely, a few tumors display unambiguous T-cell infiltration (exome CDR3 positive), but 
expression of the TCRB gene is too low to detect CDR3 sequences in the transcriptome. This result underscores 
the importance of studying T-cell infiltration by DNA or histology based methods for a more quantitative assess-
ment of their level of infiltration, in contrast to RNA-based methods, which can be confounded by the regulation 
of the TCRB gene expression.
The majority (54%) of tumors with CDR3 reads in the exome displayed only one clonotype sequence and 
the number of clonotypes identified increased with the fraction of CDR3 reads identified (Fig. 4d). Indeed, in 
contrast to deep repertoire sequencing, our approach is not deep enough to saturate the T-cell clonal diversity 
and thus provides only a shallow view of the repertoire. Similarly, the number of clonotypes identified in the 
transcriptome data increased with the fraction of CDR3 reads (Fig. 4e). Importantly, the ratio of clonotypes to 
the normalized CDR3 read count could be used to approximate clonal diversity. This measurement had a large 
variance but was consistent between DNA and RNA (Fig. 4f, r = 0.11, p = 0.02). We observed a total of 839 and 
7,130 different clonotypes across all tumors using the exome and transcriptome data, respectively, and 11 patients 
shared at least one clonotype between their tumor RNA and DNA. Oligo-clonality of the TCR repertoire could 
increase the chances of observing shared clonotypes between RNA and DNA of the same tumor, especially at 
shallow depth. However, none of these 11 tumors had noticeably low clonotype diversity (Fig. 4f), in agreement 
with the substantial under-sampling of the TCRB repertoire.
We next identified clonotypes shared between patients’ exomes (Supplementary Table S3). Two DNA clono-
types were shared between in 2 and 66 tumors, respectively. The most shared clonotype (66 tumors, referred to as 
c66) was also identified in the blood DNA of 36 of these patients and of an additional 40 patients. This suggests 
that the c66 clone was not tumor-specific, and may be directed against an antigen present relatively frequently in 
the population. Importantly, we did not find any significant association between the presence of the c66 clone and 
the patient HLA type (Supplementary Table S4), indicating that this TCR clone is likely reacting to a promiscuous 
antigen. Similarly, we did not identify a specific association of the c66 clone in patients with mutations in PIK3CA, 
GATA3, or TP53, the most common breast cancer driver genes (Supplementary Table S5).
Discussion
The study of the tumor immune-environment is particularly challenging given the complexity of the immune 
response and of the variety of host-tumor interactions. Furthermore, there is a critical lack of immune-specific 
molecular and histological observations in large cohorts of human samples. While the immune response is highly 
Figure 3. Association with survival. (a) Distribution of tumors by breast cancer histological subtypes at 
increasing iDNA scores, (b,c), Kaplan-Meier survival analysis of Her2+ patients as a function of iDNA score 
(b) and TIL content (c) with significance of the Cox proportional hazard ratio. Hazard ratio is 3.17 [1.18–8.51], 
p = 0.022 for iDNA, and 0.462 [0.151–1.142], p = 0.176 for TIL.
www.nature.com/scientificreports/
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patient-specific, large cohort studies can nevertheless inform on the global dynamics and diversity of the immune 
response. In this report, we used the breast cancer cohort from the TCGA, which is the most comprehensive 
molecularly annotated breast cancer cohort, to characterize further their immune-microenvironment.
Our study is complementary to the analysis of immune-gene expression signatures and presents a method to 
characterize T-cell infiltration directly from the bulk tumor DNA. We were specifically inspired by similar strate-
gies using “junk” or unaligned reads from genome-wide tumor sequencing to identify non-canonical information 
such as mitochondrial DNA sequence30, telomere length31, microsatellites32–34, pathogens35 or B-cell repertoire23. 
In order to detect CDR3 reads in bulk exome or transcriptome sequencing, we used existing algorithms that were 
designed to analyze TCR targeted sequencing, either by multiplex PCR or RT-PCR. Importantly, they all used a 
pre-defined set of reference V, D, and J gene combinations, together with local re-alignment and error correction. 
The tethering to the current reference TCR gene annotation may be limiting the sensitivity of the approach, 
including the exome approach we used, and de novo assembly of fully rearranged TCR genes may be preferred 
but has yet to be reliably implemented. We think, however, that our approach has a high specificity since 72% of 
the CDR3 reads detected in the exome were present in the deep TCR repertoire, which was generated using an 
independent PCR based method.
We show the clinical utility of the resulting iDNA score in Her2+ breast cancer. This result is consistent with 
previous reports11 and is likely due to the use of anti-Her2 therapy in most patients36, making the iDNA score 
a predictive rather than prognostic marker. Our analysis also suggests that it has higher value over global his-
tological measurement of TILs in Her2+ patients. We did not find any prognostic value of TILs or iDNA score 
for TNBC or HR+ /Her2− tumors with our analysis. Other studies of TNBC have shown that TIL infiltration is 
Figure 4. TCRB expression and clonal diversity. (a) Correlation between overall TCRB expression (x-axis) 
and CDR3 read abundance in RNA (y-axis), r = 0.69. (b) Distribution of the normalized CDR3 read count from 
RNA-seq at each iDNA score. (c) Distribution of the TCRB expression level in groups of tumors where CDR3 
reads can be identified in neither DNA nor RNA (D − R− ), DNA only (D + R− ), RNA only (D − R+ ) or both 
(D + R+ ) (p < 0.001 by ANOVA). (d) The number of clonotypes identified increases with the fraction of CDR3 
reads in the exome dataset (x-axis). (e) The number of clonotypes identified increases with the fraction of CDR3 
reads in the RNA-seq dataset (x-axis). (f) The T-cell clonal diversity, determined by the number of clonotypes 
divided by the normalized CDR3 read count, is similar in transcriptome (x-axis) and exome (y-axis) datasets. 
Two-dimensional density is represented (blue lines), as well as eleven tumors sharing clonotypes between DNA 
and RNA (red dots).
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associated with a decreased rate of distant recurrence36, or with better survival after neo-adjuvant treatment37. 
Unfortunately, the TCGA cohort does not have sufficient information about distant recurrence and the patients 
were not treated with neo-adjuvant therapy, therefore limiting our ability to replicate previous observations. 
The survival association obtained in Her2+ patients highlights the overall predictive value of infiltrating T-cells 
when antibody therapy is used. A similar approach could be used to interrogate TCGA data for the predic-
tive value of immune profiles and T-cell infiltration for other monoclonal antibody therapies such as cetuximab 
in EGFR-mutated non-small cell lung cancer patients38. Therefore, the iDNA score, or other genomic-derived 
measures of immune infiltration, can enrich the collection of biomarkers available on public datasets and 
that can be tested for clinical associations. However, to establish their clinical utility, these associations would 
have to be validated using assays dedicated to the evaluation of the immune-cell infiltration such as qPCR or 
immuno-histochemistry.
Immuno-histochemistry and flow cytometry are traditionally used to characterize the tumor immune com-
partment and develop immune biomarkers9. However, these measurements typically lack the information about 
the clonal identity and diversity of the adaptive immune cells. Deep TCR repertoire sequencing has been used 
to study the relevance of clonal diversity in various cancers17–21. Low clonal diversity in the blood (divpenia) is 
associated with shorter survival in metastatic breast cancer patients diagnosed with lymphopenia39. The deep 
sequencing of several regions of a large clear cell renal carcinoma shows a high heterogeneity of the clonal cell 
distribution19. Furthermore, the TILs in colorectal adenocarcinomas are more oligoclonal (lower diversity) than 
the lymphocyte population characterized from non-adjacent normal mucosa from the same patient17, further 
suggesting that the diversity is dictated by the tumor biology and neo-antigen reactivity rather than by organ spe-
cific biology. The analysis of B-cell receptor (BCR) diversity through the TCGA RNA-Seq data showed evidence 
of oligo-clonality in basal-like and Her2− enriched breast cancer23. Similarly, RNA-Seq data has also been used to 
characterize TCRA/B clonotype diversity and association with MHC class II expression, but survival associations 
were not studied40. Elsewhere, a limited number of TCGA exomes have been used to identify TCR sequences, 
further supporting the feasibility of the approach we present here41. The tumor TCR repertoire identified in our 
study is shallow – 79% of tumors with fewer than 10 clonotypes from RNA or DNA – but broad – 7,954 clono-
types (RNA or DNA) identified in 944 patients. Importantly, we identify only 2 clonotypes in common between 
patients, suggesting the absence of a dominant public T-cell clonotype and underscoring the exquisite patient 
specific immune response in breast cancer. A previous deep repertoire study reported 29 out of 32,000 clonotypes 
shared between 2 of 15 colorectal cancer patients17, a proportion consistent with our observations in a shallow 
TCGA repertoire. Furthermore, it has been proposed that the clonal composition of lymphocytes differs between 
tumor, lymph nodes and in the circulation, the repertoire being locally shaped by the presence of tumor specific 
antigens19. Our data suggests that 7 T-cell clonotypes in 41 patients are also present in the circulation and there-
fore less likely to be directed at tumor specific antigens. This implies that the study of the tumor infiltrating T-cell 
repertoire requires the analysis of a synchronous matched blood or draining lymph node control to accurately 
identify tumor specific clonotypes, or determine their rate of tumor residency versus recirculation.
Additional studies are needed to fully understand the regional variation of the repertoire and its consequences 
on cancer progression and response. Nevertheless, the value of TCR repertoire sequencing may be in monitoring 
the clonal evolution within a patient or tumor rather than in the identification of a broad-spectrum tumor specific 
antigen or its corresponding T-cell clone.
Methods
Deep T-cell repertoire sequencing. Matched frozen – formalin-fixed, paraffin-embedded (FFPE) tis-
sue samples from three triple negative breast cancer (TNBC) tumors were obtained from Asterand Biosciences 
(Detroit, MI). These samples were selected for having mirrored specimens from FFPE blocks and fresh frozen 
tissue. A pathology inspection of hematoxylin and eosin (H&E) stained sections indicates that two tumors have 
histological evidence of TILs greater than 40%, while one sample was devoid of TILs as estimated and used 
as a negative control For each FFPE sample, we extracted DNA from ten 10 μ M sections using the QIAamp 
DNA FFPE tissue kit (Qiagen, Venlo, Netherlands). The deep TCRB repertoire libraries were prepared using 
the ImmunoSeq kit (Adaptive Biotechnologies, Seattle, WA) following the manufacturer’s instructions. Briefly, 
10 μ g of DNA from each sample was split into 2 replicate (survey depth) to perform the 1st PCR amplification 
(30 cycles). The entire product was then purified using the magnetic beads, eluted in 10 μ M and subjected to 
the 2nd PCR amplification (7 cycles). The resulting indexed libraries were pooled and sequenced in one run of a 
MiSeq using ImmunoSeq custom read1 and index primers and sequenced for 150 bp (+ 6 bp index read) using 
MiSeq reagents v3. The raw sequencing data was uploaded to Adaptive Biotechnologies’ server for analysis via the 
ImmunoSeq analyzer web application.
Breast tumor exome sequencing. The sequencing libraries were prepared and captured using the 
SureSelect Human All Exon V4 kit (Agilent Technologies, Santa Clara, CA) following the manufacturer’s 
instructions. Briefly, 500 ng DNA was fragmented by Adaptive Focused Acoustics (E220 Focused Ultrasonicator, 
Covaris, Woburn, MA) to produce an average fragment size of ~175 bp and purified using the Agencourt AMPure 
XP beads (Beckman Coulter, Fullerton, CA). The quality of the fragmentation and purification was assessed with 
the Agilent 2100 Bioanalyzer. The fragment ends were repaired and adaptors were ligated to the fragments. The 
resulting DNA library was amplified by using the manufacturer’s recommended PCR conditions: 2′ at 98 °C fol-
lowed by 6 cycles of (98 °C 30″ ; 65 °C 30″ ; 72 °C 1′ ) finished by 10′ at 72 °C. 500 ng of each library was captured by 
solution hybridization to biotinylated RNA library baits for 48 hrs. at 65 °C. Bound genomic DNA was purified 
with streptavidin coated magnetic Dynabeads (Invitrogen, Carlsbad, CA) and further amplified to add barcoding 
adapters using manufacturer’s recommended PCR conditions: 2′ at 98 °C followed by 12 cycles of (98 °C 30″; 
57 °C 30″ ; 72 °C 1′ ) finished by 10′ at 72 °C. The library was sequenced on one lane of HiSeq 2500 (PE 100 pb 
www.nature.com/scientificreports/
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reads). The resulting reads were mapped to hg19 using bwa-mem42 and duplicate reads were removed using 
Picard MarkDuplicates (http://broadinstitute.github.io/picard/).
Identification of CDR3 reads. The reads mapped to the human TCRB region (hg19: chr7:142,000,817–
142,510,993) and the unmapped reads were extracted from the BAM files, and converted to fastq using 
SAMtools43 and BEDtools44. The tools ClonotypeR25, MiTCR27, and IMSEQ26 were used to identify rearranged 
TCR regions from the resulting files. Human TCR references were provided by MiTCR and IMSEQ. We cre-
ated our own reference for ClonotypeR as specified in the documentation. In short, we downloaded reference 
sequences for TCRA, B, and G from GenBank45, manually aligned the V and J segments on the conserved motifs 
using SeaView46, and separated out the segments from before or after the conserved motifs. We compared the per-
formance of the three tools, matching on read ID. When the read ID was not available from the results (MiTCR), 
we retrieved it by aligning all reads (BWA) to a reference consisting of MiTCR output reads. For each tool, the 
number of CDR3 reads detected was normalized by the total number of reads sequenced for that sample.
TCGA sample selection and data access. We retrieved the complete genomic data and clinical data from 
TCGA (http://cancergenome.nih.gov/). We selected patients with both: (1) primary tumor (no metastases) exome 
BAM files aligned to GRCh37-lite (for multiple versions, the latest was kept), and (2) known fraction of TILs. 
There were a total of 1078 breast cancer patients following these criteria. We also retrieved, for the same patients, 
when available: (3) blood exome BAM files aligned to GRCh37-lite, (4) RNA-seq tumor BAM files aligned to 
hg19, (5) known ER, PR, and Her2 status, (6) vital status/know days to last contact/days to death. The clinical 
data was retrieved from TCGA data portal for BRCA on 4/27/15. Survival analysis was done using the R “sur-
vival” package47. The sequencing data was accessed from the CGHub48. The normalized tumor gene expression 
values and the gene mutational status were retrieved from Broad Institute Firebrowse (http://dx.doi.org/10.7908/
C18W3CNQ). TCRB expression was missing from the FireBrowse datasets. In order to evaluate expression from 
TCRB, we retrieved reads mapped to the TCRB gene region from RNA-seq data for each patient from CGHub. We 
extracted the number of reads mapped to this region, and normalized by the total number of reads to calculate a 
TCRB expression value.
Gene set enrichment analysis. We used the LM22 gene signature matrix13, which defines gene sets for 22 
immune cell types, totaling 547 genes. We used Gene Set Variation Analysis (GSVA)29 to evaluate enrichment of 
these signatures in each sample using the Firebrowse expression data. This analysis was performed in R using the 
“gsva” package29. Clusters were defined by hierarchical clustering of the patients by their LM22 enrichment scores.
HLA haplotype calling. Blood normal whole-exome sequencing data was downloaded from TCGA for 
the BRCA cohort. HLA class I types were identified through a consensus approach of three tools: optitype49, 
athlates50, and snp2hla51. Allele assignments were selected for cases when two or three tools agreed, and when the 
tools did not agree, alleles were assigned by optitype, as it has the highest reported accuracy49. HLA class II types 
were identified by merging the results of athlates and snp2hla, since each covered a different subset of the genes.
Simulations of CDR3 read detection. The ratio of the length of the CDR3 VDJ region (50 bp) to the total 
length of a captured exome (50M bp) can be used to estimate the sensitivity to detect CDR3 reads in an exome 
sequencing experiment. The parameters used were (1) off target ratio of 20% (fraction of reads mapped outside 
of the exome) and (2) a CDR3 detection sensitivity of 50%. This latter parameter is derived from the fraction of 
TCRB exons captured by the Agilent SureSelect v4 (69/107 based on Gencode v19 annotation52, as well as imper-
fect mapping (fraction of reads spanning CDR3 detectable by IMSEQ depends on the length of the reads and the 
position of CDR3 reads across the VDJ junction).
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